Clinical Trial

Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 24, 2024 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of the sutdy is to evaluate efficacy, safety and immunogenicity of Recombinant Zoster Vaccine (CHO Cell) with 2 doses at 2-month interval in adults aged 40 years and older.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-06-02; most recent amendment 2024-10-22.
Status change: Not Yet Recruiting → Active, Not Recruiting 2024-10-22
Trial Details
NCT Number NCT06447779
Lead Sponsor MAXVAX Biotechnology Limited Liability Company
Conditions Herpes Zoster
Enrollment 25,000 participants
Start Date 2024-07-13
Primary Completion 2025-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2024-10-24